Petros pharmaceuticals petros pharmaceuticals developing artificial intelligence technology for phase 2 equivalent study for stendra(r)

New ai/machine learning tool designed to help potential users more effectively self-select in the effort to make stendra the first erectile dysfunction (ed) medication available otc petros in discussions with third-party technology partners new york, ny / accesswire / october 30, 2023 / petros pharmaceuticals, inc. (nasdaq:ptpi), ), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces the development of a technological component of its self-selection study utilizing machine learning/artificial intelligence (ai), which the company plans to integrate into its self-selection studies for its erectile dysfunction drug stendraÒ (avanafil). the development of the technology and study design will continue to follow direct u.s. food and drug administration (fda) recommendations as well as published proposed guidelines currently being finalized by the agency.
PTPI Ratings Summary
PTPI Quant Ranking